Open AccessMetformin and Intravascular Contrast Media: What to do in Patients Receiving Both: a Narrative Review
Author(s) -
Moghadaseh Shams,
Pooneh Dehghan,
Farhad Hosseinpanah
Publication year - 2017
Publication title -
shilap revista de lepidopterología
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.338
H-Index - 12
eISSN - 2340-4078
pISSN - 0300-5267
DOI - 10.22037/nbm.v5i3.14850
Subject(s) - metformin , medicine , renal function , lactic acidosis , contrast induced nephropathy , nephropathy , contrast (vision) , impaired renal function , diabetes mellitus , intensive care medicine , urology , endocrinology , computer science , artificial intelligence
Metformin-associated lactic acidosis (M-ALA) is considered to be one of the complications caused by intravascular contrast media (CM) administration in diabetics especially those with coexisting renal or cardiac impairment. We focused on the necessity and duration of metformin suspension in diabetics with normal or impaired renal function scheduled for CT scan with IV contrast. Searching PubMed, Web of Science, and Scopus databases, we reviewed the latest relevant guidelines as well as articles published from 1994 to 2015. There is no global consensus among different guidelines on the duration of the Metformin suspension before CT scan with IV contrast. Also, lack of substantial evidence supporting M-ALA encourages specialists to take a less conservative approach. It is safe to continue Metformin in patients with normal renal function who have no co-morbidities. In cases of equivocal renal function (30
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom